Celsion Corporation with ticker code (CLSN) now have 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 5 and 4 calculating the average target price we see 4.5. With the stocks previous close at 2.26 this indicates there is a potential upside of 99.1%. There is a 50 day moving average of 1.61 and the 200 day moving average is 0.94. The market capitalisation for the company is $161m. Visit the company website at: http://www.celsion.com
Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.